Display options
Cite
Peresypkina A, Pazhinsky A, Danilenko L, et al. Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate. Biology (Basel). 2020;9(3)doi: 10.3390/biology9030045.
Peresypkina, A., Pazhinsky, A., Danilenko, L., Lugovskoy, S., Pokrovskii, M., Beskhmelnitsyna, E., Solovev, N., Pobeda, A., Korokin, M., Levkova, E., Gubareva, V., Korokina, L., Martynova, O., Soldatov, V., & Pokrovskii, V. (2020). Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate. Biology, 9(3), . https://doi.org/10.3390/biology9030045
Peresypkina, Anna, et al. "Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate." Biology vol. 9,3 (2020). doi: https://doi.org/10.3390/biology9030045
Peresypkina A, Pazhinsky A, Danilenko L, Lugovskoy S, Pokrovskii M, Beskhmelnitsyna E, Solovev N, Pobeda A, Korokin M, Levkova E, Gubareva V, Korokina L, Martynova O, Soldatov V, Pokrovskii V. Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate. Biology (Basel). 2020 Feb 28;9(3). doi: 10.3390/biology9030045. PMID: 32121045; PMCID: PMC7150877.
Copy Download .nbib Format: NLM
Share it on

Biology (Basel). 2020 Feb 28;9(3). doi: 10.3390/biology9030045.

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate.

Biology

Anna Peresypkina, Anton Pazhinsky, Lyudmila Danilenko, Sergey Lugovskoy, Mikhail Pokrovskii, Evgeniya Beskhmelnitsyna, Nikolai Solovev, Anna Pobeda, Mikhail Korokin, Elena Levkova, Victoria Gubareva, Liliya Korokina, Olga Martynova, Vladislav Soldatov, Vladimir Pokrovskii

Affiliations

  1. Department of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
  2. Research Institute of Pharmacology of Living Systems, Belgorod State National Research University, Belgorod 308015, Russia.

PMID: 32121045 PMCID: PMC7150877 DOI: 10.3390/biology9030045

Abstract

An important task of pharmacology is to find effective agents to improve retinal microcirculation and resistance to ischemia. The purpose of the study is to pharmacologically evaluate the retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate in a rat model of retinal ischemia-reperfusion. A retinal ischemia-reperfusion model was used, in which an increase in intraocular pressure (IOP) to 110 mmHg was carried out within 30 min. The retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate at a dose of 3.8 mg/kg, in comparison with nicotinic acid at a dose of 2 mg/kg and emoxipine at a dose of 2 mg/kg, was estimated by the changes in the eye fundus during ophthalmoscopy, the retinal microcirculation level with laser Doppler flowmetry (LDF), and electroretinography (ERG) after 72 h of reperfusion. The use of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate prevented the development of ischemic injuries in the fundus and led to an increase in the retinal microcirculation level to 747 (median) (lower and upper quartiles: 693;760) perfusion units (

Keywords: 2-ethyl-3-hydroxy-6-methylpyridine nicotinate; electroretinography; laser Doppler flowmetry; ophthalmoscopy; retinal ischemia

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Curr Eye Res. 2019 Dec 27;:1-10 - PubMed
  2. Clin Exp Ophthalmol. 2006 Jan-Feb;34(1):54-63 - PubMed
  3. Biochim Biophys Acta. 2016 Dec;1864(12):1787-1800 - PubMed
  4. Mol Vis. 2018 May 18;24:367-378 - PubMed
  5. Curr Eye Res. 2018 Aug;43(8):1032-1040 - PubMed
  6. J Clin Invest. 2011 Apr;121(4):1429-44 - PubMed
  7. J Cereb Blood Flow Metab. 2010 Dec;30(12):1962-71 - PubMed
  8. Farmakol Toksikol. 1984 Jan-Feb;47(1):53-7 - PubMed
  9. Oxid Med Cell Longev. 2019 Jul 9;2019:8407206 - PubMed
  10. Graefes Arch Clin Exp Ophthalmol. 2020 Feb;258(2):335-344 - PubMed
  11. Antioxidants (Basel). 2017 Jun 03;6(2): - PubMed
  12. Indian J Ophthalmol. 1987;35(5-6):91-3 - PubMed
  13. Graefes Arch Clin Exp Ophthalmol. 2013 Aug;251(8):1873-84 - PubMed
  14. Curr Eye Res. 2017 Dec;42(12):1650-1658 - PubMed
  15. Sci Rep. 2018 Nov 9;8(1):16638 - PubMed
  16. Clin Exp Hypertens. 2017;39(8):711-717 - PubMed
  17. Bull Exp Biol Med. 2015 Jan;158(3):346-8 - PubMed
  18. J Biol Chem. 2015 Nov 6;290(45):27124-37 - PubMed
  19. Biochemistry (Mosc). 2015 Nov;80(11):1457-64 - PubMed
  20. AAPS J. 2006 Oct 06;8(4):E632-43 - PubMed
  21. Can J Ophthalmol. 2015 Apr;50(2):166-71 - PubMed
  22. Int J Mol Sci. 2019 Feb 23;20(4): - PubMed
  23. Eksp Klin Farmakol. 2013;76(5):37-47 - PubMed
  24. Molecules. 2019 Dec 31;25(1): - PubMed
  25. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12):86-90 - PubMed
  26. Cell Rep. 2017 Aug 29;20(9):2184-2200 - PubMed
  27. Int J Mol Sci. 2018 May 31;19(6): - PubMed
  28. Front Biosci. 2004 Sep 01;9:2500-20 - PubMed
  29. Arch Neurobiol (Madr). 1990 Jan-Feb;53(1):1-7 - PubMed
  30. Fundam Clin Pharmacol. 2014 Apr;28(2):180-9 - PubMed
  31. Prog Retin Eye Res. 2004 Jan;23(1):91-147 - PubMed
  32. Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):3879-3888 - PubMed
  33. Antioxidants (Basel). 2019 Feb 03;8(2): - PubMed
  34. Free Radic Biol Med. 2020 Jan;146:181-188 - PubMed
  35. J Neuroinflammation. 2019 Jun 6;16(1):118 - PubMed
  36. J Comp Neurol. 2011 Mar 1;519(4):599-620 - PubMed
  37. J Neurochem. 2013 Jul;126(2):243-60 - PubMed
  38. FEBS Open Bio. 2018 Jan 02;8(2):219-233 - PubMed
  39. Biochem Soc Trans. 2010 Aug;38(4):841-60 - PubMed
  40. Toxicol Lett. 2009 Dec 1;191(1):79-87 - PubMed
  41. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2639-2645 - PubMed
  42. Neuroscience. 2016 Jun 14;325:153-64 - PubMed
  43. Front Immunol. 2016 Oct 24;7:444 - PubMed
  44. Nanoscale. 2019 Nov 21;11(43):20667-20675 - PubMed

Publication Types